Xeris Biopharma

Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for the XeriJect drug delivery technology, aimed at developing, manufacturing, and commercializing a subcutaneous formulation of its orphan drug Tepezza (teprotumumab). The XeriJect suspensions enable concentrations exceeding 400 mg/ml, which helps to reduce injection volumes, lessen…